Show simple item record

dc.contributor.authorRivero-Juarez, A.
dc.contributor.authorVALLEJO SENRA, NICOLAU 
dc.contributor.authorLopez-Lopez, P.
dc.contributor.authorDíaz Mareque, Ana Isabel
dc.contributor.authorFrias, M.
dc.contributor.authorVallejo Alonso, Aldara Mª
dc.contributor.authorCaballero-Gómez, J.
dc.contributor.authorRodríguez Velasco, Ana 
dc.contributor.authorMOLINA PEREZ, ESTHER 
dc.contributor.authorAGUILERA GUIRAO, ANTONIO 
dc.date.accessioned2021-10-14T09:19:22Z
dc.date.available2021-10-14T09:19:22Z
dc.date.issued2019
dc.identifier.issn2076-2607
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31888090
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15537
dc.description.abstractThe hepatitis E virus (HEV) is the major cause of acute hepatitis of viral origin worldwide. Despite its usual course as an asymptomatic self-limited hepatitis, there are highly susceptible populations, such as those with underlying immunosuppression, which could develop chronic hepatitis. In this situation, implementation of therapy is mandatory in the sense to facilitate viral clearance. Currently, there are no specific drugs approved for HEV infection, but ribavirin (RBV), the drug of choice, is used for off-label treatment. Here, we present two cases of chronic HEV infection in transplant patients, reviewing and discussing the therapeutic approach available in the literature. The use of RBV for the treatment of an HEV infection in organ transplant patients seems to be effective. The recommendation of 12 weeks of therapy is adequate in terms of efficacy. Nevertheless, there are important issues that urgently need to be assessed, such as optimal duration of therapy and drug dosage.
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleRibavirin as a First Treatment Approach for Hepatitis E Virus Infection in Transplant Recipient Patients
dc.typeArtigoes
dc.authorsophosMolina Perez, Esther
dc.authorsophosAguilera Guirao, Antonio
dc.authorsophosVallejo Senra, Nicolau
dc.authorsophosRodríguez Velasco, Ana
dc.authorsophosVallejo Alonso, Aldara Mª
dc.authorsophosDíaz Mareque, Ana Isabel
dc.identifier.doi10.3390/microorganisms8010051
dc.identifier.pmid31888090
dc.identifier.sophos30942
dc.issue.number1
dc.journal.titleMICROORGANISMS
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Dixestivo
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Microbioloxía
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Nefroloxía
dc.relation.publisherversionhttps://res.mdpi.com/d_attachment/microorganisms/microorganisms-08-00051/article_deploy/microorganisms-08-00051-v2.pdf
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number8


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional